Table 2 Peritoneal Disease observed after cisplatin or cisplatin@CB[7] treatment. Pathological observations of the i.p. tumours extracted from the control, cisplatin and cisplatin@CB[7] groups. Size of tumour was determined as follows: + < 0.5 cm; ++ >0.5 cm < 1 cm; +++ >1 cm in diameter. Dissem. D. = Disseminated disease was determined as >3 small tumours spreaded throughout the peritoneal cavity
Treatment | Dissem. Disease | Attached to organ | Size of Tumours | Tumour for H&E | % of Necrotic Area |
|---|---|---|---|---|---|
Control | 6/6 | 4/6 | + | 3/6 | 11.66 ± 8.924 % |
Cisplatin i.p. | 3/6 | 3/6 | ++ | 4/6 | 32 ± 6.75 % |
Cisplatin@CB[7) i.p. | 2/6 | 4/6 | +++ | 6/6 | 47.85 ± 10.11 % |
Cisplatin@CB[7) s.c. | 0/5 | 5/5 | +++ | 4/5 | 47.5 ± 18.35 % |